Biotech Values

[mcbio]

Not to pursue high G itself at this point is a good decision IMO. Focus on the most likely to succeed with the smallest possible ph3 trial. Even if crossover explains your concern, I would not go to ph3 with high G at this point until after exploring higher than 25% cutoff for GPNMB.

If CLDX lands a partner for 011 in the not too distant future, I would fully expect a large partner to pursue high G, not to mention perhaps some of the additional potential indications for 011 beyond breast cancer, namely 3rd-line melanoma, lymphoma, osteosarcoma, squamous cell lung (CLDX disclosed these additional potential indications at the recent Lazard conference).